INCB. List of Psychotropic Substances Under International Control. Vienna, Austria: International Narcotics Control Board; 2019;V.19-08673 (E)(30th edition).
2.
Carhart-HarrisR, GiribaldiB, WattsR, et al.Trial of psilocybin versus escitalopram for depression. N Engl J Med, 2021; 384(15):1402–1411.
3.
Carhart-HarrisRL, BolstridgeM, DayCMJ, et al.Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology (Berl), 2018; 235(2):399–408.
RosaWE, SagerZ, MillerM, et al.Top ten tips palliative care clinicians should know about psychedelic-assisted therapy in the context of serious illness. J Palliat Med, 2022; 25(8):1273–1281.
7.
VehlingS, KissaneDW. Existential distress in cancer: Alleviating suffering from fundamental loss and change. Psycho-Oncology, 2018; 27(11):2525–2530.
8.
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197.
9.
GrobCS, DanforthAL, ChopraGS, et al.Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch General Psychiatry, 2011; 68(1):71.
10.
DavisAK, BarrettFS, MayDG, et al.Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry, 2021; 78(5):481.
11.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med, 2022; 387(18):1637–1648.
12.
BogenschutzMP, ForcehimesAA, PommyJA, et al.Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol, 2015; 29(3):289–299.
HendricksPS, ThorneCB, ClarkCB, et al.Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol, 2015; 29(3):280–288.
15.
YuCL, YangFC, YangSN, et al.Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis. Psychiatry Investig, 2021; 18(10):958–967.
16.
LearyT, MetznerR, AlpertR.The Psychedelic Experience: A Manual Based on the Tibetan Book of the Dead. Academic Press: London, UK; 1964.
17.
MalcolmB, ThomasK. Serotonin toxicity of serotonergic psychedelics. Psychopharmacology, 2022; 239(6):1881–1891.
18.
StuderusE, KometerM, HaslerF, et al.Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J Psychopharmacol, 2011; 25(11):1434–1452.
JohnsonMW, GriffithsRR, HendricksPS, et al.The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018; 142:143–166.
GasserP, HolsteinD, MichelY, et al.Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Mental Dis, 2014; 202(7):513–520.
23.
KrebsTS, JohansenP-Ø. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol, 2012; 26(7):994–1002.
24.
Palhano-FontesF, BarretoD, OniasH, et al.Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med, 2019; 49(4):655–663.
25.
WolfsonPE, AndriesJ, FeducciaAA, et al.MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci Rep, 2020; 10(1):20442.
